Details of patients in CAMZYOS group who required temporary discontinuation of drug due to LVEF <50% during placebo-controlled phase (Week 0–16) of VALOR-HCM²

No patients in either group were unblinded during the study period.

Adapted from Desai M et al. 2022.²
AE, adverse event; D, day; DC, discontinuation; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; NYHA, New York Heart Association; W, week.

Details of patients in CAMZYOS group who required temporary discontinuation of drug due to LVEF <50% during placebo-controlled phase (Week 0–16) of VALOR-HCM2

Details of patients in CAMZYOS group who required temporary discontinuation of drug due to LVEF <50% during placebo-controlled phase (Week 0–16) of VALOR-HCM²